Company: INTS
Filing Date: 2025-04-25
Form Type: 424B4
Source: 0001628280-25-020056
Chunk: 21

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-25
Form: 424B4
Chunk 21
---
 outstanding warrants to purchase Common Stock with a weighted average exercise price of $4.32 per share; and

• 1,881,649 additional shares of the Common Stock reserved for future issuance under our equity incentive plans, plus 529,300 additional shares of the Common Stock reserved for future issuance under our equity incentive plans authorized on January 1, 2025.

Unless otherwise indicated, the discussion and table above assume no exercise of the outstanding options and warrants described above after December 31, 2024 and excludes the shares of Common Stock to be issued upon exercise of the Common Warrants offered in this offering.

<div align='center'>14</div>

### DILUTION
If you invest in our securities in this offering, your ownership interest will be diluted to the extent of the difference between the public offering price per share of our Common Stock in this offering and the pro forma as adjusted net tangible book value per share of our Common Stock after the closing of this offering.

As of December 31, 2024, our historical net tangible book value was $2.8 million, or $0.18 per share of Common Stock. Our historical net tangible book value per share is equal to our total tangible assets, less total liabilities, divided by the number of outstanding shares of Common Stock as of December 31, 2024.

After giving further effect to the sale of 3,133,333 shares of Common Stock and accompanying Common Warrants to purchase up to 6,266,666 shares of our Common Stock in this offering based on a public offering price of $0.75 per share, and after deducting Placement Agents’ fees and estimated offering expenses payable by us, and assuming no exercise of the Common Warrants issued in connection with this offering, our pro forma as adjusted net tangible book value as of December 31, 2024 would have been $4.7 million, or $0.26 per share of Common Stock. This represents an immediate increase in pro forma as adjusted net tangible book value of $0.08 per share to our existing shareholders and an immediate dilution of $0.49 per share to investors participating in this offering based on the public offering price. We determine dilution per share to investors participating in this offering by subtracting pro forma as adjusted net tangible book value per share after this offering from the public offering price per share paid by investors participating in this offering.

The following table illustrates this dilution on a per share basis:

| Public offering price per share                                                              |